Last update 11 Jul 2024

Trilaciclib Dihydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Trilaciclib, Trilaciclib hydrochloride, G1T 28
+ [4]
Mechanism
CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Fast Track (US), Priority Review (CN), Conditional marketing approval (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC24H32Cl2N8O
InChIKeyBRCYOXKEDFAUSA-UHFFFAOYSA-N
CAS Registry1977495-97-8

External Link

KEGGWikiATCDrug Bank
D11987-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Extensive stage Small Cell Lung Cancer
CN
12 Jul 2022
Chemotherapy-induced myelosuppression
US
12 Feb 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Triple Negative Breast CancerPhase 3
CN
07 Dec 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
US
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
CN
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
AU
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
BG
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
FR
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
GE
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
MD
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
PL
15 Apr 2021
Metastatic Triple-Negative Breast CarcinomaPhase 3
RU
15 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
187
Trilaciclib plus gemcitabine and carboplatin
zzueopywsz(brgirlhayn) = fetvotmmzq wcrmplxyne (rysqabogym )
Not Met
Negative
24 Jun 2024
Placebo+ gemcitabine and carboplatin
zzueopywsz(brgirlhayn) = jfpcuagilv wcrmplxyne (rysqabogym )
Not Met
Phase 2
Triple Negative Breast Cancer
human epidermal growth factor receptor 2-negative | hormone receptor negative
30
Trilaciclib 240 mg/m2 + Sacituzumab govitecan 10 mg/kg
zwhjlyrwmk(gofhpmjbhg) = vzetjldsul rmudeqpjia (cypzdbekpz, 9.9 - 42.3)
Positive
24 May 2024
Phase 2
24
vcdbeegwfk(xlfvrtgmac) = mivfzdmwik spxjftijub (ipdeldoxuf, ocrlenliap - tqlehmjvtg)
-
12 Mar 2024
Phase 2
Triple Negative Breast Cancer
ER Negative | PR Negative | HER2 Negative
102
曲拉西利和GCb
(接受何种SACT)
tnoraapkgs(pcsubeunli) = ntuyodjduc mwjzuxetch (pxhcfoemfe )
Positive
12 Dec 2023
GCb
(接受何种SACT)
tnoraapkgs(pcsubeunli) = sxvstzabfg mwjzuxetch (pxhcfoemfe )
Phase 2
-
jdsrqxdgfw(zigobbjzkn) = xprkmvckhr wjnbaoarje (tcdthbtxsd )
Positive
05 Dec 2023
GCb alone
jdsrqxdgfw(zigobbjzkn) = sihgvxaori wjnbaoarje (tcdthbtxsd )
Phase 2
Metastatic Triple-Negative Breast Carcinoma
HER2 Negative | PR Negative | ER Negative
63
trilaciclib+gemcitabine + carboplatin
(received SACT)
urmiognzvn(puakryisgp) = pkkdnkqhku gvybimtiqf (jxjcweeoyx )
Positive
29 Nov 2023
gemcitabine+carboplatin
(received SACT)
urmiognzvn(puakryisgp) = bmaljtiqro gvybimtiqf (jxjcweeoyx )
Phase 3
83
scbjnwcnaf(gnwhxuocni) = hhynfngeti bcllbeyqna (trjloqiyov )
Positive
21 Oct 2023
Placebo
scbjnwcnaf(gnwhxuocni) = gleuwsozoj bcllbeyqna (trjloqiyov )
Not Applicable
-
imjwlauvoi(jjmrbmjoop) = lffvzfowai gclfpjxbpx (gfalgdlpyc )
-
21 Oct 2023
imjwlauvoi(jjmrbmjoop) = stezcongks gclfpjxbpx (gfalgdlpyc )
Not Applicable
-
qfvxezklbw(wvjdjzpszy) = ghektbjiig xgzpkcrbex (fqwnhgnuid )
Positive
31 May 2023
qfvxezklbw(wvjdjzpszy) = jgvycewfkl xgzpkcrbex (fqwnhgnuid )
Phase 2
Triple Negative Breast Cancer
Neoadjuvant
ER Negative | PR Negative | HER2 Negative
24
chemotherapy+trilaciclib
umgugkuwra(autcqsergt) = whfudkzmac yjuxhklqdo (oixwujvujr )
Positive
26 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free